Abbott Laboratories (VIE:ABT)
Austria · Delayed Price · Currency is EUR | Market Cap | 152.19B -23.3% |
| Revenue (ttm) | 40.78B +8.1% |
| Net Income | 4.73B -61.2% |
| EPS | 2.71 -61.2% |
| Shares Out | n/a |
| PE Ratio | 32.19 |
| Forward PE | 16.85 |
| Dividend | 2.18 (2.51%) |
| Ex-Dividend Date | Oct 15, 2026 |
| Volume | n/a |
| Open | 88.18 |
| Previous Close | 87.68 |
| Day's Range | 86.98 - 88.36 |
| 52-Week Range | 70.10 - 116.08 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 21, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium HMB (beta-hydroxy-beta-methylbuty...
Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can sig...
Abbott hosts conference call for third-quarter earnings
ABBOTT PARK, Ill., Sept. 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2026 financial results on Wednesday, Oct. 21, before the market opens.
Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio
Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help eligib...
Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
Partnership combines Abbott's Lingo continuous glucose monitor with Berry Street's insurance-covered registered dietitian support, helping consumers translate glucose insights into healthier behaviors...
Abbott declares 411th consecutive quarterly dividend
ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
Abbott to pay $384 mln over contaminated infant formula allegations, US Justice Dept says
Abbott Laboratories has agreed to pay more than $384 million to settle allegations related to contaminated infant formula, the U.S. Justice Department said on Monday.
Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall
Settlement does not represent any finding of fault or liability As the government has previously indicated, it has closed its criminal investigation on this matter Tests by government regulators of un...
Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases St...
Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
New Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support bab...
Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication Amulet 360 builds upon Abbott's first-generation LAA device with design updat...
FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients
The U.S. Food and Drug Administration said on Tuesday it authorized Abbott Laboratories' glucose monitor, making it the first device that continuously monitors both ketone levels and blood sugar.
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
Libre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for...
Abbott agrees to $670 million settlement of infant formula cases
Abbott said on Thursday it reached a $670 million settlement with three law firms to resolve legal claims by 2,000 people who alleged harms relating to the company's specialty formulas for preterm i...
Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
Agreements will resolve the Gill case and claims involving approximately 2,000 other individuals Abbott and the medical community stand by the safety of preterm infant formulas Regulators and medical ...
Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
The NACHC and Abbott Food for Health Initiative is a multi-year "food is medicine" effort to support the integration of nutrition as a foundational component of primary care provided by Community Heal...
Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
"We Give Blood" brings together all 18 Big Ten® schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its hist...
Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership includes a...
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader acces...
Abbott defeats shareholder lawsuit over 2022 infant formula recall
A federal judge on Friday dismissed a lawsuit accusing Abbott Laboratories of defrauding shareholders by downplaying and trying to evade its responsibility for a 2022 recall of powdered infant formu...
Abbott investigates two separate cyber incidents, says no operations affected
Abbott Laboratories is investigating two cyber incidents involving unauthorized access to some internal systems at its cancer diagnostics business and its LabCentral portal, the company said on Frid...
Abbott Laboratories Earnings Call Transcript: Q2 2026
Second quarter sales grew 4.8% with adjusted EPS of $1.31, exceeding expectations. Full-year sales growth guidance was reaffirmed and EPS guidance raised, with strong momentum in nutrition, diagnostics, and medical devices. Key product launches and pipeline investments support future growth.
Abbott Laboratories Earnings release: Q2 2026
Abbott Laboratories released its Q2 2026 earnings on July 16, 2026, summarizing the period's financial results.
Abbott Laboratories Slides: Q2 2026
Abbott Laboratories has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.